For example, the joint utilization of the MEK inhibitor selumetinib and ceritinib has been proven to show significant therapy effect on MAP2K1K57N activation mutation of MEK NSCLC cell line, and dual blockage of ALK/MEK can overcome even delay the ALK-TKL resistance (105). Here, MAP2K7 is linked to non-small cell lung carcinoma.